StreetInsider.com News Articles

Form 8-K MUSTANG BIO, INC. For: Oct 13

Thu, 15 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261015/27193393.html

Form 8-K MUSTANG BIO, INC. For: Oct 13

Thu, 15 Oct 2026 16:06:00 -0400

si-local-file:///var/storage/secattach/20261015/27193393.html

Form 8-K Fortress Biotech, Inc. For: Sep 30

Thu, 01 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261001/27136512.html

Form 4 Fortress Biotech, Inc. For: Oct 01 Filed by: Jin David

Thu, 01 Oct 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20261001/27136496.html

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Journey Medical Corporation to Participate in September 2026 Investor Conferences

Tue, 08 Sep 2026 16:05:00 -0400

SCOTTSDALE, Ariz., Sept. 08, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (“Journey Medical”) (Nasdaq: DERM), a commercial-stage pharmaceutical company focused on developing, selling and marketing U.S. Food and Drug Administration (“FDA”)-approved prescription pharmaceutical products for the treatment of dermatological conditions, today announced that Claude Maraoui, Co-Founder, President and Chief Executive Officer, will participate in two September 2026 investor conferences.

Details of the events are as follows:

Lake Street Capital Markets 10th Annual Best Ideas Growth (BIG10) Conference
Date: Thursday, September 10, 2026
Location: New York City
Format: 1x1 Meetings

H.C. Wainwright

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on Friday, September 11, 2026, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference

Fortress Biotech to Present at the H.C. Wainwright 28th Annual Global Investment Conference

Tue, 08 Sep 2026 08:00:00 -0400

MIAMI, Sept. 08, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty income, today announced that Lindsay A. Rosenwald, M.D., Chairman, President and Chief Executive Officer, will present a corporate overview at the H.C. Wainwright 28th Annual Global Investment Conference. The presentation will be available for on-demand viewing by conference attendees starting on Friday, September 11, 2026, at 7:00 a.m. ET. The Company will also attend one-on-one meetings during the conference

Form 10-Q Fortress Biotech, Inc. For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

http://archive.fast-edgar.com/20260813/AKBE4Q2C8Z22UZZK22ZD2ZZZBCUSZ2W2Z28Q

Filed on: August 13, 2026

Form 10-Q Fortress Biotech, Inc. For: Jun 30

Thu, 13 Aug 2026 16:32:00 -0400

http://archive.fast-edgar.com/20260813/AKBE4Q2C8Z22UZZK22ZD2ZZZBCUSZ2W2Z28Q

Filed on: August 13, 2026

Form 8-K Fortress Biotech, Inc. For: Aug 13

Thu, 13 Aug 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260813/26921351.html

Form 8-K Fortress Biotech, Inc. For: Aug 13

Thu, 13 Aug 2026 16:16:00 -0400
si-local-file:///var/storage/secattach/20260813/26921351.html

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025

Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO^® and UNLOXCYT™

MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty

Fortress Biotech Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Thu, 13 Aug 2026 16:05:00 -0400

Total net revenue increased 14% to $18.7 million for second quarter of 2026 compared to second quarter of 2025

Partnered programs continue to advance with Crystalys Therapeutics announcing its $130 million Series B financing to support the late-stage global development and commercialization preparation for dotinurad, and royalties generated from the launches of ZYCUBO^® and UNLOXCYT™

MIAMI, Aug. 13, 2026 (GLOBE NEWSWIRE) -- Fortress Biotech, Inc. (Nasdaq: FBIO) (“Fortress”), an innovative biopharmaceutical company focused on acquiring and advancing assets to enhance long-term value for shareholders through product revenue, equity holdings and dividend and royalty

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved

Journey Medical Corporation Reports Second Quarter 2026 Financial Results and Recent Corporate Highlights

Wed, 12 Aug 2026 16:01:00 -0400

Total revenues were $18.5 million for the second quarter of 2026, reflecting 23% growth from the prior-year quarter

Emrosi^® revenues were $8.1 million for the second quarter of 2026

Strong revenue growth and disciplined cost management continue drive to profitability

Company to hold conference call today at 4:30 p.m. ET

SCOTTSDALE, Ariz., Aug. 12, 2026 (GLOBE NEWSWIRE) -- Journey Medical Corporation (Nasdaq: DERM) (“Journey Medical,” “the Company,” “we” or “our”), a commercial-stage pharmaceutical company focused on developing, selling and marketing FDA-approved

Form 10-Q MUSTANG BIO, INC. For: Jun 30

Wed, 05 Aug 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260805/26873650.html

Form 10-Q MUSTANG BIO, INC. For: Jun 30

Wed, 05 Aug 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260805/26873650.html

Form 10-Q MUSTANG BIO, INC. For: Jun 30

Wed, 05 Aug 2026 16:02:00 -0400
si-local-file:///var/storage/secattach/20260805/26873650.html